Find Your Fit: 4 New Additions to the Belkin SoundForm Audio Collection Announced at IFA 2024
5.9.2024 11:00:00 EEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced 4 new products across its SoundForm audio category, underscoring Belkin innovation, quality and its commitment to building products more responsibly. Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905446437/en/
Belkin announces new SoundForm portfolio at IFA 2024 (Photo: Business Wire)
Designed in its in-house labs at Belkin Global Headquarters in California, every SoundForm product undergoes 150 meticulous quality tests, ensuring perfection before it reaches consumer’s ears. Design, sound quality, comfort, voice-calling performance, enhanced features and value are all considered with each new addition to the SoundForm portfolio.
Belkin Signature Sound is integrated throughout the SoundForm range. Developed by Belkin sound engineers, it allows the wearer to listen to music exactly the way the artist intended. Deep bass is balanced, vocals are crystal-clear, and treble is crisp. To do this, Belkin sound engineers test headphone and earphone frequency response and distortion, passive noise isolation, Environmental Noise Cancellation (ENC), Active Noise Cancellation (ANC) performance, and Sound Pressure Level (SPL) to ensure proper 98db output for ‘adult’ products and 85db ‘safe sound’ for ‘kids’ products—and more. All new SoundForm products feature ENC for voice isolating clear call quality as standard.
Consumers will find a product in the SoundForm collection to suit their needs–all without breaking the bank.
SoundForm Rhythm
The SoundForm Rhythm earbuds pack a punch while taking up minimal space. They were designed for consumers looking for a casual pair of earbuds for entertainment, work/study purposes, or daily use.
Features:
- Design: True wireless, stem-shaped
- Sound: 6mm drivers
- Battery life: 8 hours with an additional 20 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $34.99 / £24.99 / €29.99
Availability: SoundForm Rhythm is available now on belkin.com and select retailers worldwide
SoundForm ClearFit
Get a (good) grip with the SoundForm ClearFit. When it’s time to move, ClearFit is a go-to. Perfect for sports, outdoor activities and workouts, these earbuds stay comfortably secured around the outer ear for great sound while allowing the user to stay aware of their surroundings.
Features:
- Design: Open-ear, secure, comfortable and IPx5 sweat resistant
- Sound: 14.2mm drivers
- Battery life: 8 hours with an additional 18 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £39.99 / €49.99
Availability: SoundForm ClearFit is available now on belkin.com/de and belkin.com/uk and select retailers worldwide
SoundForm Isolate
The SoundForm Isolate is the first over-ear headphone with ANC by Belkin. Made for the modern and stylish individual, Isolate provides quality ANC at a reasonable price point. In addition to ANC, Isolate also has a built-in “Relaxation” track that plays on a loop for moments where you need to further tune out external noise. They come with a long battery life of 60 hours, 3 settings (Standard Listening, Active Noise Cancellation, Hear Thru Mode) and Bluetooth multipoint – all in a sleek and portable design.
Features:
- Design: Over-ear, foldable, extendable and comfortable with 5 mics and intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours of battery life (40 hours with ANC on)
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £49.99 / €59.99
Availability: SoundForm Isolate will be available from Autumn 2024
SoundForm Surround
The SoundForm Surround over-ear headphones are perfect for when you need to chat on the go. ENC ensures clear calls with background noise kept to a whisper. Its foldable, extendable, and comfortable over-ear design and intuitive touch controls make SoundForm Surround an everyday accessory.
Features:
- Design: Over-ear, foldable, extendable and comfortable with intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $39.99 / £29.99 / €39.99
Availability: SoundForm Surround will be available from Autumn 2024
All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products. They will be on display at IFA 2024.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905446437/en/
Contacts
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom